

Our Ref: 596

August 2024

Freedom of Information Act Request

Request for Information under the Freedom of Information Act 2000

I am analysing the usage of new biologic and targeted medications within dermatology medicine.
Could you please answer the following question:

How many patients were treated in September 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) - 0
- Baricitinib (Olmiant) - 2
- Dupilumab (Dupixent) - 15
- Lebrikizumab (Ebglyss) - 0
- Omalizumab (Xolair) - 0
- Tralokinumab (Adtralza) - 0
- Upadacitinib (Rinvoq) - 0